Artificial intelligence (AI)-enabled in vitro diagnostics company Renalytix AI has partnered with AstraZeneca to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases.

In the first stage of the collaboration, Renalytix AI’s AI-based in vitro diagnostic platform KidneyIntelX will be used to evaluate improving outcomes for patients with chronic kidney disease (CKD) and its complications.

Based on the study outcomes, the companies also plan to initiate a multi-centre, randomised controlled trial.

The study will evaluate uptake and adherence to new potassium-binding agents in CKD and hyperkalemia patients.

It will improve guideline-based standard-of-care for optimal utilisation of existing and novel therapeutics, using the KidneyIntelX testing platform and proprietary care management software.

The studies will be conducted in coordination with the Mount Sinai Health System, where KidneyIntelX testing and care management software are presently being deployed for commercial clinical use.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

RenalytixAI board member Barbara Murphy said: “We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases such as kidney disease, diabetes and cardiovascular disease.

“By using a more personalised approach, our initial goal is to help realise improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.”

AstraZeneca US Renal-Cardio vice-president Tarek Rabah said: “This collaborative approach reflects the shared vision of AstraZeneca and RenalytixAI to develop meaningful solutions to tackle significant challenges in healthcare in a holistic way.

“We are committed to revolutionising kidney care by continuing to drive innovation. An important component of our work is identifying patients with significant unmet need and providing them with more personalised interventions.”

CKD affects nearly 37 million adults in the US. More than 850 million people are estimated to be affected by CKD and acute kidney injury (AKI), and are on renal replacement therapy (RRT) globally.